- The Wall Street Journal•14 minutes ago
The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.
- Market Realist•8 hours ago
Copaxone 40 mg litigations On August 24, 2016, Mylan (MYL) announced that the PTO (US Patent and Trademark Office) invalidated patents 8,232,250 and 8,399,413, which are related to Teva Pharmaceutical…...
- Moody's•10 hours agoTeva Pharmaceutical Industries Ltd -- Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative
New York, August 25, 2016-- Moody's Investors Service commented that the Patent Trial and Appeal Board's invalidation of two of Teva's patents on Copaxone 40 mg is credit negative. However, there is no ...
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||51.30 x 1000|
|Ask||51.60 x 200|
|Day's Range||51.11 - 52.29|
|52wk Range||48.01 - 66.55|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.20|
|Avg Vol (3m)||5,712,746|
|Dividend & Yield||1.36 (2.56%)|